Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients

NCT03873987 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Bacterial Skin and Skin Structure Infection

Interventions

DRUG: Current Formulation of Oritavancin
DRUG: Kimyrsa

Sponsor

Melinta Therapeutics, Inc.